Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 6/2021

07.09.2021 | Invited Editorial

Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have Enough Evidence to Solve the Dilemma?)

verfasst von: José Luis Merino, Juan Tamargo

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Excerpt

Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with significant impairment in functional capacity and quality of life and increased morbidity and mortality [1‐3]. Indeed, AF is independently associated with an overall 3.5-fold risk increase of mortality, which is predominantly due to increased risk of stroke and systemic embolic events (S/SE) and ventricular dysfunction [4]. Non-anticoagulated patients with AF have a 3- to 5 fold increased risk of ischemic strokes, and it is estimated that up to 30% of all ischemic strokes and 10% of cryptogenic strokes are related to this arrhythmia [1‐3]. Furthermore, ischemic strokes associated with AF are nearly twice as likely to be fatal and generally more severe and more recurrent than strokes unrelated to AF [5, 6]. …
Literatur
1.
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20:e1-160.PubMedCrossRef
2.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2019;16:e66-93.PubMedCrossRef
3.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.PubMedCrossRef
4.
Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: a Report From the American Heart Association. Circulation. 2021;143:e254–743.PubMedCrossRef
5.
Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation The Framingham Study. Stroke. 1996;27:1760–4.PubMedCrossRef
6.
Hayden DT, Hannon N, Callaly E, Ní Chróinín D, Horgan G, Kyne L, et al. Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: a population study. Stroke. 2015;46:3488–93.PubMedCrossRef
7.
Arbelo E, Brugada J, Blomstrom-Lundqvist C, Laroche C, Kautzner J, Pokushalov E, et al., on the behalf of the ESC EHRA Atrial Fibrillation Ablation Long-term Registry Investigators. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017;38:1303-16.
8.
Nyong J, Amit G, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, et al. Efficacy and safety of ablation for people with nonparoxysmal atrial fibrillation. Cochrane Database Syst Rev. 2016;11:CD012088.PubMed
9.
Siontis KC, Ioannidis JPA, Katritsis GD, Noseworthy PA, Packer DL, Hummel JD, et al. Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-Analysis of Quality of Life, Morbidity, and Mortality. JACC Clin Electrophysiol. 2016;2:170–80.PubMedCrossRef
10.
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA Randomized Clinical Trial. JAMA. 2019;321:1261–74.PubMedPubMedCentralCrossRef
11.
Vassilikos VP, Pagourelias ED, Laroche C, Blomström-Lundqvist C, Kautzner J, Maggioni AP, et al. AFA LT registry investigators group. Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. Europace. 2021;23:49–58.PubMedCrossRef
12.
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378:417-427.
13.
Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133:1637–44.PubMedCrossRef
14.
Samuel M, Abrahamowicz M, Joza J, Beauchamp ME, Essebag V, Pilote L. Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure. Europace. 2020;22:739–47.PubMedPubMedCentralCrossRef
15.
Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol. 2017;70:1949–61.PubMedCrossRef
16.
Noseworthy PA, Van Houten HK, Gersh BJ, Packer DL, Friedman PA, Shah ND, et al. Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020;17:1057–65.PubMedPubMedCentralCrossRef
17.
Barra S, Baran J, Narayanan K, Boveda S, Fynn S, Heck P, et al. Association of catheter ablation for atrial fibrillation with mortality and stroke: a systematic review and meta-analysis. Int J Cardiol. 2018;266:136–42.PubMedCrossRef
18.
Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. 2019;12:e007414.PubMedCrossRef
19.
Briceño DF, Madan N, Romero J, Londoño A, Villablanca PA, Natale A, et al. Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives. Expert Opin Drug Saf. 2017;16:769–77.PubMedCrossRef
20.
Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–8.PubMedCrossRef
21.
De Greef Y, Stroker E, Schwagten B, Kupics K, De Cocker J, Chierchia GB, et al. Complications of pulmonary vein isolation in atrial fibrillation: predictors and comparison between four different ablation techniques: results from the Middelheim PVI-registry. Europace. 2018;20:1279–86.PubMedCrossRef
22.
Steinbeck G, Sinner MF, Lutz M, Müller-Nurasyid M, Kääb S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. Eur Heart J. 2018;39:4020–9.PubMedPubMedCentralCrossRef
23.
Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol. 2012;5:302–11.PubMedCrossRef
24.
Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–44.PubMedCrossRef
25.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis Task Force on anticoagulants in heart disease. Thromb Haemost. 2013;110:1087–107.PubMedCrossRef
26.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.PubMedCrossRef
27.
Cappato R,Marchlinski FE,Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, et al. VENTURE-AF Investigators Uninterrupted rivaroxaban vs uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805–11.
28.
Kuwahara T, Abe M, Yamaki M, Fujieda H, Abe Y, Hashimoto K, et al. Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol. 2016;27:549–54.PubMedCrossRef
29.
Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Grimaldi M; RE-CIRCUIT investigators. Uninterrupted Dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–36.
30.
Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39:2942–55.PubMedPubMedCentralCrossRef
31.
Reynolds MR, Allison JS, Natale A, Weisberg IL, Ellenbogen KA, Richards M, et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU Trial. JACC Clin Electrophysiol. 2018;4:580–8.PubMedCrossRef
32.
Hohnloser SH, Camm J, Cappato R, Diener H-C, Heidbüchel H, Mont L, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40:3013–21.PubMedPubMedCentralCrossRef
33.
Zhao Y, Yang Y, Tang X, Yu X, Zhang L, Xiao H. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol. 2017;48:267–82.PubMedCrossRef
34.
Atti V, Turagam MK, Viles-Gonzalez JF, Lakkireddy D. Anticoagulation After Catheter Ablation of Atrial Fibrillation: is it time to Discontinue in Select Patient Population? J Atr Fibrillation. 2018;11:2092.PubMedPubMedCentralCrossRef
35.
Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis. J Thromb Thrombolysis. 2018;45:550–6.PubMedCrossRef
36.
Zhao Y, Lu Y, Qin Y. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. Int J Cardiol. 2018;270:167–71.PubMedCrossRef
37.
Cardoso R, Knijnik L, Bhonsale A, Miller J, Nasi G, Rivera M, et al. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. 2018;15:107–15.PubMedCrossRef
38.
Proietti R, AlTurki A, Di Biase L, China P, Forleo G, Corrado A, Marras E, Natale A, Themistoclakis S. Anticoagulation after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2019;30:468–78.PubMedCrossRef
39.
Romero J, Cerrud-Rodriguez RC, Alviz I, Diaz JC, Rodriguez D, Arshad S, et al. Significant benefit of uninterrupted DOACs versus VKA during catheter ablation of atrial fibrillation. JACC Clin Electrophysiol. 2019;5:1396–405.PubMedCrossRef
40.
Romero J, Cerrud-Rodriguez RC, Diaz JC, Rodriguez D, Arshad S, Alviz I, et al. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2019;30:1250–7.PubMedCrossRef
41.
Ottóffy M, Mátrai P, Farkas N, Hegyi P, Czopf L, Márta K, Garami A, Balaskó M, Pótóné-Oláh E, Mikó A, Rostás I, Wobbe B, Habon T. Uninterrupted or minimally interrupted direct oral anticoagulant therapy is a safe alternative to vitamin k antagonists in patients undergoing catheter ablation for atrial fibrillation: an updated meta-analysis. J Clin Med. 2020;9:3073.PubMedCentralCrossRef
42.
Yang P, Wang C, Ye Y, Huang T, Yang S, Shen W, et al. Interrupted or uninterrupted oral anticoagulants in patients undergoing atrial fibrillation ablation. Cardiovasc Drugs Ther. 2020;34:371–81.PubMedCrossRef
43.
Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace. 2013;15:1407–11.PubMedCrossRef
44.
Providência R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace. 2014;16:1137–44.PubMedCrossRef
45.
Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace. 2014;16:1443–9.PubMedPubMedCentralCrossRef
46.
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.PubMedCrossRef
47.
Wagstaff AJ, Overvad TF, Lip GYH, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM. 2014;107:955–67.PubMedCrossRef
48.
Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep. 2016;6:27410.PubMedPubMedCentralCrossRef
49.
Nuotio I, Hartikainen JEK, Grönberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312:647–9.PubMedCrossRef
50.
Garg A, Khunger M, Seicean S, Chung MK, Tchou PJ. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. J Am Coll Cardiol EP. 2016;2:487–94.
51.
Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118:2171–87.PubMedPubMedCentralCrossRef
52.
Nührich JM, Kuck KH, Andresen D, Steven D, Spitzer SG, Hoffmann E, et al. Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol. 2015;104:463–70.PubMedCrossRef
53.
Freeman JV, Shrader P, Pieper KS, Allen LA, Chan PS, Fonarow GC, et al. Outcomes and anticoagulation use after catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2019;12:e007612.PubMedCrossRef
54.
Mardigyan V, Verma A, Birnie D, Guerra P, Redfearn D, Becker G, et al. Anticoagulation management pre- and post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol. 2013;29:219–23.PubMedCrossRef
55.
Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, Reich S, Igic P, Elmouchi D, Tschopp D, Wimmer A, Dey S, Crawford T, Pelosi F Jr, Jongnarangsin K, Bogun F, Morady F. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006;114:759–65.PubMedCrossRef
56.
Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, Di Biase L, Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans DJ, Haissaguerre M, Raviele A, Natale A. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55:735–43.PubMedCrossRef
57.
Yagishita A, Takahashi Y, Takahashi A, Fujii A, Kusa S, Fujino T, et al. Incidence of late thromboembolic events after catheter ablation of atrial fibrillation. Circ J. 2011;75:2343–9.PubMedCrossRef
58.
Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes. J Interv Card Electrophysiol. 2013;38:147–53.PubMedPubMedCentralCrossRef
59.
Karasoy D, Gislason GH, Hansen J, Johannessen A, Køber L, Hvidtfeldt M, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 2015;36:307–14.PubMedCrossRef
60.
Noseworthy PA, Yao X, Deshmukh AJ, Van Houten H, Sangaralingham LR, Siontis KC, et al. Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc. 2015;4:e002597.PubMedPubMedCentralCrossRef
61.
Gallo C, Battaglia A, Anselmino M, Bianchi F, Grossi S, Nangeroni G, et al. Long-term events following atrial fibrillation rate control or transcatheter ablation: a multicenter observational study. J Cardiovasc Med (Hagerstown). 2016;17:187–93.CrossRef
62.
Själander S, Holmqvist F, Smith JG, Platonov PG, Kesek M, Svensson PJ, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JAMA Cardiol. 2017;2:146–52.PubMedCrossRef
63.
Liang JJ, Elafros MA, Mullen MT, Muser D, Hayashi T, Enriquez A, et al. Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2018;29:823–32.PubMedCrossRef
64.
Yang WY, Du X, Jiang C, He L, Fawzy AM, Wang L, et al. The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study. Europace. 2020;22:90–9.PubMedCrossRef
65.
Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost. 2018;118:768–77.PubMedCrossRef
66.
Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65:2481–93.PubMedCrossRef
67.
Chao TF, Liao JN, Tuan TC, Lin YJ, Chang SL, Lo LW, et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients. Thromb Haemost. 2019;119:1162–70.PubMedCrossRef
68.
Weijs B, Dudink E, de Vos CB, Limantoro I, Tieleman RG, Pisters R, et al. Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study. Neth Heart J. 2019;27:487–97.PubMedPubMedCentralCrossRef
69.
Potpara TS, Larsen TB, Deharo JC, Rossvoll O, Dagres N, Todd D, et al. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). Europace. 2015;17:986–93.PubMedCrossRef
70.
Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation. 2019;140:1639–46.PubMedCrossRef
71.
Riley MP, Zado E, Hutchinson MD, Lin D, Bala R, Garcia FC, et al. Risk of stroke or transient ischemic attack after atrial fibrillation ablation with oral anticoagulant use guided by ECG monitoring and pulse assessment. J Cardiovasc Electrophysiol. 2014;25:591–6.PubMedCrossRef
72.
Yanagisawa S, Inden Y, Fujii A, Ando M, Funabiki J, Murase Y, et al. Uninterrupted direct oral anticoagulant and warfarin administration in elderly patients undergoing catheter ablation for atrial fibrillation: a comparison with younger patients. JACC Clin Electrophysiol. 2018;4:592–600.PubMedCrossRef
73.
Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes AM, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation beforeand after catheter ablation (DISCERN AF). JAMA Intern Med. 2013;173:149–56.PubMedCrossRef
74.
Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli on the basis of stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8:1416–23.PubMedCrossRef
75.
Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016;37:1591–602.PubMedCrossRef
76.
Chao TF, Ambrose K, Tsao HM, Lin YJ, Chang SL, Lo LW, et al. Relationship between the CHADS2 score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. Heart Rhythm. 2012;9:1185–91.PubMedCrossRef
77.
Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al.; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120-9.
78.
Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474–80.PubMedCrossRef
79.
Liang JJ, Callans DJ. Can anticoagulation be stopped after ablation of atrial fibrillation? Curr Cardiol Rep. 2020;22:58.PubMedCrossRef
80.
Cheung CC, Krahn AD, Andrade JG. The emerging role of wearable technologies in detection of arrhythmia. Can J Cardiol. 2018;34:1083–7.PubMedCrossRef
81.
Jones NR, Taylor CJ, Hobbs FDR, Bowman L, Casadei B. Screening for atrial fibrillation: a call for evidence. Eur Heart J. 2020;41:1075–85.PubMedCrossRef
82.
Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM Study. JAMA Cardiol. 2018;3:601–8.PubMedPubMedCentralCrossRef
Metadaten
Titel
Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have Enough Evidence to Solve the Dilemma?)
verfasst von
José Luis Merino
Juan Tamargo
Publikationsdatum
07.09.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2021
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07246-3

Weitere Artikel der Ausgabe 6/2021

Cardiovascular Drugs and Therapy 6/2021 Zur Ausgabe

Original Article

Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease

Original Article

Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin

Original Article

Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway

Invited Review Article

Cardioprotective Potential of Exogenous Ubiquitin

Original Article

Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective

Original Article

Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen